Faster recovery: Assists athletes, frequent travelers, or those recovering from illness in regaining strength and stamina more quickly
A GLP-1 programme for the 2.3 million Canadians who lack any payer for the obesity indication and cannot self-pay would cost approximately $2.2 billion annually in drug costs at generic equilibrium pricing comparable scale, proven administrative architecture
In recent years, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as cornerstone therapies in the management of T2D and obesity [5,6,7]
This includes the likes of caffeine anhydrous for an effective energy boost, creatine monohydrate for effective muscle building, and l-citrulline to give you intense muscle pumps with every rep
Endocrinology 158: 4139-4151, 2017